Trials / Terminated
TerminatedNCT01097369
Elitek (Rasburicase) Immuno-Monitoring Study
A Multicenter Registry Study of Anti-rasburicase Antibodies in Patients Retreated With Rasburicase (SR29142) in the Context of Relapsing Leukemia/Lymphoma Who Experienced Subsequent Hypersensitivity Reaction(s) or Loss of Uricolytic Activity: An Immuno-Monitoring Observational Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.
Conditions
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2010-04-01
- Last updated
- 2013-01-31
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01097369. Inclusion in this directory is not an endorsement.